Nestlé’s $1 bn sale of its vitamins and minerals unit to Yellow Wood Partners sharpens its focus on core nutrition businesses
Executive summary: Nestlé agreed to sell its vitamins and minerals business to Yellow Wood Partners for about $1 billion. The divestiture lets Nestlé focus on higher‑margin categories and streamline its portfolio amid pressure to improve returns.
Who is involved: Nestlé (Swiss food giant), Yellow Wood Partners (US private‑equity firm), and the vitamins‑and‑minerals business unit.
Likely next: Completion pending regulatory approvals, integration of the unit under Yellow Wood, and Nestlé reallocating the proceeds to core businesses or shareholder returns.
Nestlé has agreed to sell its global vitamins and minerals business to US private‑equity firm Yellow Wood Partners for approximately $1 billion. The move aligns with the company’s strategy to concentrate resources on areas where it claims the strongest competitive advantage. The transaction is expected to close after customary antitrust reviews, with proceeds likely used to strengthen Nestlé’s core portfolio or returned to shareholders.
Timeline
- — Nestlé vend son activité vitamines et minéraux à l'américain Yellow Wood Partners pour 1 milliard de dollars (Le Figaro — Économie)
Analysis — what this means
Likely next events
- Antitrust clearance expected from the European Commission by Q1 2027
- Hart‑Scott‑Rodino filing review by the US FTC anticipated within 4‑6 months
- Yellow Wood plans to pursue add‑on acquisitions in the nutritional supplements space within 18 months
Sectors affected
- Dietary supplements manufacturing
- Vitamins and minerals production
- Private‑equity‑owned consumer health
Regulatory implications
- EU Merger Regulation review by the European Commission – decision expected Q1 2027
- US Hart‑Scott‑Rodino antitrust filing – review by the Federal Trade Commission, timeline 4‑6 months
- Potential notification to UK Competition and Markets Authority if overlapping UK sales exceed thresholds
Historical parallels
- Nestlé’s 2015 sale of its skin health business to Eurazeo for €2.4 bn
- Novartis’ 2018 divestment of its over‑the‑counter business to GSK for $13 bn
- Bayer’s 2020 sale of its consumer health business to Kohlberg Kravis Roberts for $10 bn